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Medical abortion for an early pregnancyUnintended or incidental pregnancy is still a major health
issue because it poses appreciable medical, emotional, social,
and financial costs on women, their families, and society [1].
Although surgical abortion through either vacuum aspiration
or dilatation and curettage has been a well-known method to
successfully manage an early pregnancy since the 1960s, the
risk of the surgical procedure and anesthesia is often consid-
ered. Alternative therapy, including medical treatment, for
early pregnancy termination, is always welcomed. The
combined use of misoprostol, a prostaglandin analog that had
a strong uterotonic effect in the 1970s, and mifepristone, an
antiprogestogen, which was used to block the receptors for
progesterone and glucocorticosteroid and increase the sensi-
tivity of the uterus to prostaglandins in the 1980s, has been
found to be more effective than single agents [2]. Therefore,
the use of medical abortion has the potential to expand
abortion services and expand the woman’s choice of
abortion method and experience [2], although there is still
inadequate evidence to comment on the acceptability and side
effects of medical compared with surgical first-trimester
abortions [3].
Because the use of medical abortion to terminate early
pregnancy is already widely available in some countries and
increasingly available throughout the world, it is important to
identify the best available agents and regimen for use. In this
issue, Dr. Li et al [4] decreased the dose of misoprostol from
800 to 600 mg and wanted to minimize the potential side
effects of medical abortion after the use of a combination of
mifepristone and misoprostol, and the results were impressive.
For example, the incidence of cramping was decreased from
nearly 100% to 72%, compared with the conventional dosage
of 800 mg reported in the literature. In addition, gastrointes-
tinal discomfort, such as nausea and vomiting, was also
dramatically decreased (32% vs. 60% and 15% vs. 30%,
respectively). The striking effect was dizziness. The incidence
in the present study was less than 10% compared with more
than 40% in previous studies [5,6]. The success rate of the
combination of 600 mg misoprostol and 200 mg mifepristone
in this study was around 95%, which was not significantly
inferior to that of previous studies [5,6]. It is reasonable to
suppose that this combination might be an appropriate treat-
ment for women at less than 49 days of gestational age in
Taiwan, although some questions need further clarification.1028-4559/$ - see front matter Copyright  2011, Taiwan Association of Obstetri
doi:10.1016/j.tjog.2011.01.001A head-to-head comparison between the combination of
600 mg misoprostol and 200 mg mifepristone and the combi-
nation of 800 mg misoprostol and 200 mg mifepristone would
be worthwhile. In addition, it is not clear whether the presence
or absence of a positive fetal heart will affect the occurrence of
side effects or therapeutic outcome. Finally, it is unclear
whether this regimen can be applied to more advanced
gestational age, such as 63 days of gestational age. In fact, the
comparison between the present study and other published
studies might not be fair because the populations of the other
studies, except for the study by Murthy et al [5], had a more
advanced gestational age [6,7].
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